Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Operating Leases (2019 - 2025)

Regenxbio (RGNX) has 7 years of Operating Leases data on record, last reported at $65.2 million in Q4 2025.

  • For Q4 2025, Operating Leases fell 12.03% year-over-year to $65.2 million; the TTM value through Dec 2025 reached $65.2 million, down 12.03%, while the annual FY2025 figure was $65.2 million, 12.03% down from the prior year.
  • Operating Leases reached $65.2 million in Q4 2025 per RGNX's latest filing, down from $67.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $88.8 million in Q4 2022 and bottomed at $65.2 million in Q4 2025.
  • Average Operating Leases over 5 years is $79.6 million, with a median of $82.3 million recorded in 2021.
  • Peak YoY movement for Operating Leases: skyrocketed 1062.78% in 2021, then fell 12.03% in 2025.
  • A 5-year view of Operating Leases shows it stood at $84.9 million in 2021, then grew by 4.56% to $88.8 million in 2022, then fell by 7.41% to $82.2 million in 2023, then fell by 9.84% to $74.1 million in 2024, then decreased by 12.03% to $65.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $65.2 million in Q4 2025, $67.4 million in Q3 2025, and $69.6 million in Q2 2025.